Navigation Links
Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
Date:10/28/2010

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the third quarter ended September 30,2010 on Wednesday, November 3, 2010 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time.

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (800) 884-5695 (domestic) or (617) 786-2960 (international), participant code 70229939. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave®. The U.S. Food and Drug Administration (FDA) has scheduled the Endocrinologic and Metabolic Drugs Advisory Committee meeting on December 7, 2010 and the Prescription Drug User Fee Act (PDUFA) action date has been set for January 31, 2011. The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
2. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
3. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
4. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
5. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
6. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
7. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
10. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
11. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014  Discovery Laboratories, ... has been awarded a Phase II Small Business ... $3.0 million from the National Institute of Allergy ... of Health (NIH) to support the development of ... a medical countermeasure to mitigate acute and chronic/late-phase ...
(Date:10/1/2014)... Oct. 1, 2014 Pfanstiehl has announced ... EP), manufactured in the USA ... long been recognized for playing a key role ... body of evidence that media supplementation with mannose ... protein glycosylation," according to Dr. Christopher Wilcox ...
(Date:10/1/2014)... 2014 In response to its ... address sales, training and consumer engagement challenges, ... mobile applications to turn their clients’ visions into ... customized mobile app creations, are now featured on ... partnership with Toyota, StudioPMG created a robust cross-platform ...
(Date:10/1/2014)... TeselaGen Biotechnology has received a ... their bioCAD/CAM software suite, which uses synthetic biology ... Business Innovation Research Phase II grant will be used ... from the Lawrence Berkeley National Laboratory. j5 was developed ... laboratory that develops alternative fuel technologies for the Department ...
Breaking Biology Technology:Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Digital Agency Studio PMG Launches New Case Studies on Website 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3
... Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) announced today that it ... Equity Conference to be held August,18-19, 2008 at the ... of Access is scheduled to speak on Monday, August ... and will give a corporate overview and,discuss the Company,s ...
... Anthera Pharmaceuticals,Inc., a privately held biopharmaceutical company ... a $19 Million,equity financing. New investors Caxton ... HBM BioCapital (Cayman Islands) led the financing, ... Advantage Venture Partners (the,General Partner of Caxton ...
... MS, EDMONTON, Aug. 12 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced financial and ... 2008. BioMS Medical, in partnership with Eli Lilly ... for the treatment of MS,undergoing pivotal trials in ...
Cached Biology Technology:Access Pharmaceuticals to Present at the Noble Financial Equity Conference 2Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman 2Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman 3BioMS Medical Announces Second Quarter 2008 Results 2BioMS Medical Announces Second Quarter 2008 Results 3BioMS Medical Announces Second Quarter 2008 Results 4BioMS Medical Announces Second Quarter 2008 Results 5
(Date:9/30/2014)... of the environmental effects of moorland burning is published ... subject, with the aim of relieving tensions on both ... The EMBER (Effects of Moorland Burning on the Ecohydrology ... on moorland, which is practised predominantly to support red ... on peat hydrology, peat chemistry and physical properties, river ...
(Date:9/30/2014)... comprehensive assessment conducted by the Ocean Health Index ... 100 in overall health. In addition, for the ... the 15 ocean regions beyond national jurisdiction (high-seas ... healthy climate, safeguarding biodiversity and providing sustainable food ... the index, a partnership led by scientists from ...
(Date:9/30/2014)... The National Institutes of Health (NIH) awarded Lawrence ... develop an electrode array system that will enable ... through unprecedented resolution and scale. , LLNL,s grant-funded ... President Obama,s BRAIN (Brain Research through Advancing ... to revolutionize our understanding of the human mind ...
Breaking Biology News(10 mins):Grouse moor burning causes widespread environmental changes 2Rating the planet's oceans 2Rating the planet's oceans 3NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3
... of modern-day birds took to the skies by gliding ... and legs, according to new research by a University ... journal Paleobiology, Department of Biological Sciences PhD student Nick ... taking off from the ground while running and shows ...
... role in mediating the outcome of competition between rival ... in the New World--or, on a much smaller ecological ... to competing bacteria. In a new study, researchers have ... with one another, and they have found that each ...
... directly comparing weight-loss outcomes in super-obese patients, researchers ... newer operation, the duodenal switch, produced substantially better ... gastric bypass. , In the October issue of ... the duodenal switch (DS) produced greater weight loss ...
Cached Biology News:Ancient birds flew on all-fours 2Different strategies underlie the ecology of microbial invasions 2For super-obese patients, duodenal switch beats gastric bypass 2For super-obese patients, duodenal switch beats gastric bypass 3
For testing the AQUA technique on your MS instruments....
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
A Highly Purified, Cost-Effective Taq DNA Polymerase...
...
Biology Products: